Is it safe?
Can ARQT take a bad year?
Arcutis Biotherapeutics, Inc. holds $130M more cash than debt, so a bad year is a question about profits, not about lenders.
$130M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 6.10
Altman Z-score · safe zone, above 3
- Interest cover
- 2.47×
Interest cover · operating profit covers the interest bill, with room to spare
Details›
- Total debtQ2 2026
- $109M
- Cash and short-term investments
- $239M
- Net cash
- $130M
- Operating profit, trailing twelve months
- $34M
- Debt / equity
- 0.49×
- Annualised volatilitytwo years of daily moves
- 63%
- Worst drawdown on file
- −95%
- Below its 52-week high
- −19%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.